Home  »  Trending   »  Looking Closely at the Growth Curve for Lineage Ce...

Looking Closely at the Growth Curve for Lineage Cell Therapeutics Inc. (LCTX)

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp

Lineage Cell Therapeutics Inc. (AMEX:LCTX) went down by -6.93% from its latest closing price compared to the recent 1-year high of $3.13. The company’s stock price has collected -9.18% of loss in the last five trading sessions. Press Release reported on 01/04/22 that Lineage Cell Therapeutics to Present at H.C. Wainwright Bioconnect Virtual Conference

Is It Worth Investing in Lineage Cell Therapeutics Inc. (AMEX :LCTX) Right Now?

Plus, the 36-month beta value for LCTX is at 1.74. Opinions of the stock are interesting as 5 analysts out of 6 who provided ratings for Lineage Cell Therapeutics Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 1 rated it as “hold,” and 0 as “sell.”


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored


The average price from analysts is $6.40, which is $4.52 above the current price. LCTX currently public float of 161.00M and currently shorts hold a 4.93% ratio of that float. Today, the average trading volume of LCTX was 1.16M shares.

LCTX’s Market Performance

LCTX stocks went down by -9.18% for the week, with a monthly drop of -5.05% and a quarterly performance of -21.01%, while its annual performance rate touched -7.84%. The volatility ratio for the week stands at 8.03% while the volatility levels for the past 30 days are set at 8.52% for Lineage Cell Therapeutics Inc.. The simple moving average for the period of the last 20 days is -18.28% for LCTX stocks with a simple moving average of -24.27% for the last 200 days.

Analysts’ Opinion of LCTX

Many brokerage firms have already submitted their reports for LCTX stocks, with Noble Capital Markets repeating the rating for LCTX by listing it as a “Outperform.” The predicted price for LCTX in the upcoming period, according to Noble Capital Markets is $8 based on the research report published on August 19th of the previous year 2021.

Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see LCTX reach a price target of $6. The rating they have provided for LCTX stocks is “Overweight” according to the report published on March 31st, 2021.

LCTX Trading at -17.98% from the 50-Day Moving Average

After a stumble in the market that brought LCTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -39.97% of loss for the given period.

Volatility was left at 8.52%, however, over the last 30 days, the volatility rate increased by 8.03%, as shares surge +2.17% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -21.01% lower at present.

During the last 5 trading sessions, LCTX fell by -9.18%, which changed the moving average for the period of 200-days by -16.81% in comparison to the 20-day moving average, which settled at $2.30. In addition, Lineage Cell Therapeutics Inc. saw -23.27% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at LCTX starting from Hogge Gary S., who sale 37,695 shares at the price of $2.45 back on Dec 29. After this action, Hogge Gary S. now owns 0 shares of Lineage Cell Therapeutics Inc., valued at $92,438 using the latest closing price.

Hogge Gary S., the SVP,Clinical & Medical Affairs of Lineage Cell Therapeutics Inc., sale 501,588 shares at $2.45 during a trade that took place back on Dec 28, which means that Hogge Gary S. is holding 28,445 shares at $1,228,891 based on the most recent closing price.

Stock Fundamentals for LCTX

Current profitability levels for the company are sitting at:

  • -3467.01 for the present operating margin
  • -213.58 for the gross margin

The net margin for Lineage Cell Therapeutics Inc. stands at -2671.28. The total capital return value is set at -24.95, while invested capital returns managed to touch -19.15. Equity return is now at value -10.40, with -9.60 for asset returns.

Based on Lineage Cell Therapeutics Inc. (LCTX), the company’s capital structure generated 3.43 points at debt to equity in total, while total debt to capital is 3.32. Total debt to assets is 3.06, with long-term debt to equity ratio resting at 2.64. Finally, the long-term debt to capital ratio is 2.55.

>> 7 Top Picks for the Post-Pandemic Economy <<

When we switch over and look at the enterprise to sales, we see a ratio of 97.40, with the company’s debt to enterprise value settled at 0.01. The receivables turnover for the company is 0.06 and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.66.

Leave a Comment

Your email address will not be published. Required fields are marked *

Heading

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam